Tag:
vorapaxar
Latest Headlines
Latest Headlines
Bleeding risk clouds Merck's hopes for vorapaxar franchise
Vorapaxar isn't shaping up to be the mega hit that Merck ( $MRK ) had hoped for.
Merck tracks positive results, bleeding risk in second big vorapaxar study
Merck says that vorapaxar , its troubled blood thinner once considered the jewel in Schering-Plough's crown when the pharma giant bought it for $41 billion, hit its primary efficacy endpoint in a
Merck's vorapaxar failed to beat placebo in key PhIII
Investigators for Merck unveiled some of the data from their failed late-stage study of the experimental blood thinner vorapaxar , noting that 18.5% in the drug arm experienced a cardiovascular event,
Merck stands by R&D plans, writes off $1.7B on vorapaxar snafu
Merck investors got another reminder today of just how painful a Phase III setback can be for the company's financial prospects. The pharma giant was forced to write off $1.7 billion for the fourth
Bleeding risk torpedoed Merck's blockbuster vorapaxar study
A week after Merck spooked analysts and investors alike by shuttering one big trial of the late-stage blockbuster contender vorapaxar while dropping a big group of patients from a second Phase
Merck shares battered after it shutters vorapaxar trial
Just days after newly named Merck CEO Ken Frazier ( photo ) singled out the anti-clotting drug vorapaxar as a star in the company's late-stage pipeline, the company slammed the brakes on one of the two
